Skip to main content
. 2015 Jun 4;9(6):e0003697. doi: 10.1371/journal.pntd.0003697

Table 1. TPP for point-of-care diagnosis for patients in the acute phase of Chagas disease.

Needs for Diagnosis Medical Conduct Samples and Sampling Infrastructure Technical Skills Testing Site, Turnaround Time Reading Taxonomic Diagnosis Sensitivity Specificity
Congenital transmission Serodiagnosis of pregnant women and women admitted at delivery living or born in endemic countries (knowing that >70% have no signs or symptoms) Samples processed individually. (i) Maximum. 2 ml of cord or peripheral blood obtained specifically for diagnostic test; (ii) Blood sample collected for routine screening for infectious or metabolic diseases; (iii) Ideal: urine sample (i) Ideal: processing at point of care; (ii) Less desirable: samples processed in a reference laboratory transported without cold chain Good laboratory practices (GLP)–trained technical staff with quality certification. Screening conducted by staff who assisted the childbirth Primary health centre (PHC), hospital or delivery institution. Ideal timing: <1 h, up to a maximum of 12 h from sampling Qualitative Single universal test should detect all circulating strains >95% 100%. Ideal: integrated into routine health care screening (e.g., metabolic screening)
Vector and oral transmission (i) Differential diagnosis for at risk population with febrile syndrome; (ii) Active search in cases of possible exposure (contacts) Samples processed individually. (i) 2–5 mL blood or serum; (ii) Ideal: urine, saliva sample (i) Ideal: processing at point of care; (ii) Less desirable: samples processed in a reference lab and transported without cold chain GLP-trained technical staff with quality certification PHC and/or community-based diagnosis facility. Ideal timing: <1 h from sampling Qualitative/quantitative Single universal test should detect all circulating strains >95% 100%. Ideal: integrated into routine health care screening (e.g., metabolic screening). Should differentiate T. cruzi from T. rangeli
Reactivation of infection associated with immune suppression in organ transplants. Blood transfusion transmission Active surveillance Samples processed individually. Blood, cerebral spinal fluid, tissue from chagoma (i) Ideal: processing at point-of-care; (ii) Less desirable: samples processed in a reference laboratory and transported without cold chain GLP-trained technical staff with quality certification Reference medical facility, blood banks, and hospital. Ideal timing: <1 h from sampling Qualitative/quantitative Single universal test should detect all circulating strains >95% 100%. Ideal: integrated into routine screening. Should differentiate between T. cruzi and T. rangeli. In the case of diagnosis in central nervous system manifestations of HIV/AIDS, it should differentiate T. cruzi from other opportunistic infections, such as toxoplasmosis.